skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: The radiation dosimetry of Re-186 HEDP

Abstract

Patients suffering from metastatic bone cancer may be offered some relief of bone pain by several palliative agents currently under study. One such agent is Re-186 HEDP (etidronate). We gathered biodistribution data from 27 patients receiving this agent for palliation of bone pain. Skeletal activity was estimated as that portion of administered activity not recovered in urine or measured in kidneys or extracellular fluid (ECF) space. Activity in kidneys was estimated through scintigraphic imaging. Activity in urine and blood were estimated by direct counting of samples; activity in ECF was approximated as blood activity divided by the plasmacrit, multiplied by 0.2 times body weight. All retention data were fit to a sum of exponentials for estimation of residence times. Activity in the urinary bladder contents was estimated from the urinary excretion data using the dynamic bladder model of Cloutier et al. Estimated residence times were kidneys 0.538 hr, bone 33.3 hr (divided evenly between cortical and trabecular bone for dosimetry purposes), urinary bladder contents 1.18 hr, and remainder of body 6.52hr. Radiation dose estimates were developed, using the MIRDOSE 3 software. Radiation dose estimates for bone surfaces and red marrow are 1.9 and 0.82 mGy/MBq, respectively. The estimate for themore » urinary bladder wall is 0.57 mGy/MBq. Most other organs` estimates were around 0.02 mGy/MBq. The new marrow dose model presented in MIRDOSE 3 was used to look at the distribution of marrow dose in different bones, and to develop a dose-volume histogram. These data should be used as the basis for the radiation dosimetry of this agent.« less

Authors:
 [1]; ;  [2]
  1. Oak Ridge Inst. for Science and Education, TN (United States)
  2. Memorial Sloan-Kettering Cancer Center, NY (United States)
Publication Date:
OSTI Identifier:
441629
Report Number(s):
CONF-950603-
Journal ID: JNMEAQ; ISSN 0161-5505; TRN: 96:002093-0054
DOE Contract Number:  
AC05-76OR00033
Resource Type:
Journal Article
Journal Name:
Journal of Nuclear Medicine
Additional Journal Information:
Journal Volume: 36; Journal Issue: Suppl.5; Conference: 42. annual meeting of the Society of Nuclear Medicine, Minneapolis, MN (United States), 12-15 Jun 1995; Other Information: PBD: May 1995
Country of Publication:
United States
Language:
English
Subject:
56 BIOLOGY AND MEDICINE, APPLIED STUDIES; 55 BIOLOGY AND MEDICINE, BASIC STUDIES; 99 MATHEMATICS, COMPUTERS, INFORMATION SCIENCE, MANAGEMENT, LAW, MISCELLANEOUS; RADIATION DOSES; M CODES; BONE MARROW; BLADDER; DOSIMETRY; EXCRETION; KIDNEYS; PATIENTS; TRABECULAR BONE; RHENIUM 186

Citation Formats

Stabin, M G, Graham, M C, and Scher, H J. The radiation dosimetry of Re-186 HEDP. United States: N. p., 1995. Web.
Stabin, M G, Graham, M C, & Scher, H J. The radiation dosimetry of Re-186 HEDP. United States.
Stabin, M G, Graham, M C, and Scher, H J. Mon . "The radiation dosimetry of Re-186 HEDP". United States.
@article{osti_441629,
title = {The radiation dosimetry of Re-186 HEDP},
author = {Stabin, M G and Graham, M C and Scher, H J},
abstractNote = {Patients suffering from metastatic bone cancer may be offered some relief of bone pain by several palliative agents currently under study. One such agent is Re-186 HEDP (etidronate). We gathered biodistribution data from 27 patients receiving this agent for palliation of bone pain. Skeletal activity was estimated as that portion of administered activity not recovered in urine or measured in kidneys or extracellular fluid (ECF) space. Activity in kidneys was estimated through scintigraphic imaging. Activity in urine and blood were estimated by direct counting of samples; activity in ECF was approximated as blood activity divided by the plasmacrit, multiplied by 0.2 times body weight. All retention data were fit to a sum of exponentials for estimation of residence times. Activity in the urinary bladder contents was estimated from the urinary excretion data using the dynamic bladder model of Cloutier et al. Estimated residence times were kidneys 0.538 hr, bone 33.3 hr (divided evenly between cortical and trabecular bone for dosimetry purposes), urinary bladder contents 1.18 hr, and remainder of body 6.52hr. Radiation dose estimates were developed, using the MIRDOSE 3 software. Radiation dose estimates for bone surfaces and red marrow are 1.9 and 0.82 mGy/MBq, respectively. The estimate for the urinary bladder wall is 0.57 mGy/MBq. Most other organs` estimates were around 0.02 mGy/MBq. The new marrow dose model presented in MIRDOSE 3 was used to look at the distribution of marrow dose in different bones, and to develop a dose-volume histogram. These data should be used as the basis for the radiation dosimetry of this agent.},
doi = {},
url = {https://www.osti.gov/biblio/441629}, journal = {Journal of Nuclear Medicine},
number = Suppl.5,
volume = 36,
place = {United States},
year = {1995},
month = {5}
}